Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase

Summary

There is a lack of evidence that long-term opioid use offers benefit for noncancer pain and an abundance of evidence of harm. The objective of the R21 pilot phase of the Application of Economics \& Social psychology to improve Opioid Prescribing Safety (AESOPS) is to develop and test novel behavioral nudges to encourage adherence to pain and CDC guidelines for opioid prescribing for persons with noncancer pain. Interventions will leverage the electronic health record (EHR) to discourage unnecessary opioid prescribing through the application of "behavioral insights"-empirically-tested social and psychological interventions that affect choice.

Conditions

• Opioid Use, Unspecified

Interventions

BEHAVIORAL

Opioid naive

Visit where the order is for an included opioid and there is no prior opioid prescription with a start date of greater than 1 day and less than 91 days

BEHAVIORAL

At-risk for long term use

Visit where the order is for an included opioid, there is a prior opioid prescription with a start date greater than 1 day and less than 91 days, and there is no prior opioid prescription with a start date greater than 90 days

BEHAVIORAL

Long-term opioid recipient

Total opioid doses are at least 50 MME per day, there are two or more prior opioid prescriptions with two different start dates both greater than 1 day and less than 91 days, and there is a prior opioid prescription with a start date greater than 90 days and less than 181 days

Sponsors & Collaborators

• National Institute on Aging (NIA)

  collaborator NIH

• Northwestern University

  collaborator OTHER

• AltaMed Health Services Corporation

  collaborator OTHER

• The Children's Clinic

  collaborator OTHER

• University of Southern California

  lead OTHER

Principal Investigators

• Jason N Doctor, PhD · University of Southern California

Study Design

Allocation

NA

Purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-03-25

Primary Completion

2019-11-30

Completion

2019-11-30

Countries

• United States

Study Locations